Biolase expands soft-tissue laser to new markets

February 8, 2013 by MassDevice staff

Biolase wins a nod from the FDA to expand its soft-tissue laser to 19 different markets.

Biolase logo

Biolase (NSDQ:BIOL) won FDA approval for the use of its 940nm Diolase 10 laser in a range of different markets. The federal watchdog agency also cleared 80 new procedures for the device.

The Irvine, Ca-based dental laser company said it can now sell into more than 20 new markets, including ear, nose and throat, arthroscopy, dermatology, plastic surgery and ophthalmology.

The Diolase 10 is used as an alternative to drills; the 940nm wavelength has also been approved for tooth whitening and pain relief, according to a press release.

Last October, Biolase won clearancefor the Epic 10 diode, which controls laser energy levels.

"We will use the clearances received for the Diolase 10, now established as a 940nm diode laser predicate device, to obtain the same clearances for our Epic 10 platform, which uses the same wavelength," CEO and CFO Fred Furry said in the release.

Comments